In vitro antimicrobial activity of "last-resort" antibiotics against unusual nonfermenting gram-negative bacilli clinical isolates

Microbial Drug Resistance

Volumn 18, Issue 4, 2012, Pages 396-401

  Jacquier, Herve ^a,b   Le Monnier, Alban ^c   Carbonnelle, Etienne ^d   Corvec, Stephane ^e   Illiaquer, Marina ^e   Bille, Emmanuelle ^f   Zahar, Jean Ralph ^f   Jauréguy, Françoise ^g   Fihman, Vincent ^h   Tankovic, Jacques ⁱ   Cattoir, Vincent ^j  

^a HÔPITAL LARIBOISIÈRE   (France)

^b INSERM   (France)

^c CENTRE HOSPITALIER DE VERSAILLES   (France)

^d Service de Bactériologie   (France)

^e UNIVERSITÉ DE NANTES   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g AVICENNE HOSPITAL   (France)

^h HÔPITAL LOUIS MOURIER   (France)

ⁱ HÔPITAL SAINT ANTOINE   (France)

^j UNIVERSITÉ DE CAEN   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; DORIPENEM; IMIPENEM; MEROPENEM; TIGECYCLINE;

ACHROMOBACTER XYLOSOXIDANS; ACINETOBACTER; ACINETOBACTER BAUMANNII; ALCALIGENES FAECALIS; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BURKHOLDERIA CEPACIA COMPLEX; DELFTIA; EPSILOMETER TEST; FRANCE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA;

ANTI-BACTERIAL AGENTS; BACTERIAL TYPING TECHNIQUES; CARBAPENEMS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE;

ACHROMOBACTER XYLOSOXIDANS; ACINETOBACTER; ACINETOBACTER BAUMANNII; ALCALIGENES FAECALIS; BACILLI (CLASS); BURKHOLDERIA CEPACIA COMPLEX; DELFTIA; NEGIBACTERIA; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA;

EID: 84864339208     PISSN: 10766294     EISSN: 19318448     Source Type: Journal    
DOI: 10.1089/mdr.2011.0195     Document Type: Article

References (30)

1. Almuzara, M., A. Limansky, V. Ballerini, L. Galanternik, A. Famiglietti, and C. Vay. 2009. In vitro susceptibility of Achromobacter spp. isolates: Comparison of disk diffusion, Etest and agar dilution methods. Int. J. Antimicrob. Agents 35:68-71.
2. Almuzara, M.N., M.I. Encalada Barzallo, A.M. Famiglietti, and C.A. Vay. 2011. Comparative activities of tigecycline and other tetracyclines against nonfermenting Gramnegative bacilli, excluding Acinetobacter spp. Antimicrob. Agents Chemother. 55:3961-3963.
3. Castanheira, M., R.N. Jones, and D.M. Livermore. 2009. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. Diagn. Microbiol. Infect. Dis. 63:426-433.
4. Chen Y.H., P.R. Hsueh, R.E. Badal, S.P. Hawser, D.J. Hoban, S.K. Bouchillon, Y. Ni, and D.L. Paterson. 2011. Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intraabdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria. J. Infect. 62:280-291.
5. Cheng, N.C., P.R. Hsueh, Y.C. Liu, J.M. Shyr, W.K. Huang, L.J. Teng, and C.Y. Liu. 2005. In vitro activities of tigecycline, ertapenem, isepamicin, and other antimicrobial agents against clinically isolated organisms in Taiwan. Microb. Drug Resist. 11:330-341.
6. Enoch, D.A., C.I. Birkett, and H.A. Ludlam. 2007. Nonfermentative Gram-negative bacteria. Int. J. Antimicrob. Agents 29 Suppl 3:S33-S41.
7. Farrell, D.J., H.S. Sader, and R.N. Jones. 2010. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob. Agents Chemother. 54:2735-2737.
8. Fihman, V., A. Le Monnier, S. Corvec, F. Jaureguy, J. Tankovic, H. Jacquier, E. Carbonnelle, E. Bille, M. Illiaquer, V. Cattoir, and J.R. Zahar, on behalf of the GMC Study group. 2012. Stenotrophomonas maltophilia-the most worrisome threat among unusual non-fermentative Gramnegative bacilli from hospitalized patients: A prospective multicenter study. J. Infect. [Epub ahead of print]; doi: 10.1016/j.jinf.2012.01.001
9. Gales, A.C., R.N. Jones, S.S. Andrade, and H.S. Sader. 2005. Antimicrobial susceptibility patterns of unusual nonfermentative gram-negative bacilli isolated from Latin America: Report from the SENTRY Antimicrobial Surveillance Program (1997-2002). Mem. Inst. Oswaldo Cruz 100:571-577.
10. Gales, A.C., R.N. Jones, and H.S. Sader. 2011. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: Results from the SENTRY Antimicrobial Surveillance Program (2006-09). J. Antimicrob. Chemother. 66:2070-2074.
11. Gales, A.C., A.O. Reis, and R.N. Jones R.N. 2001. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: Review of available interpretative criteria and quality control guidelines. J. Clin. Microbiol. 39:183-190.
12. Hoban, D.J., S.K. Bouchillon, B.M. Johnson, J.L. Johnson, and M.J. Dowzicky. 2005. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn. Microbiol. Infect. Dis. 52:215-227.
13. Jacquier, H., E. Carbonnelle, S. Corvec, M. Illiaquer, A. Le Monnier, E. Bille, J.R. Zahar, J.L. Beretti, F. Jaureguy, V. Fihman, et al. 2011. Revisited distribution of nonfermenting Gram-negative bacilli clinical isolates. Eur. J. Clin. Microbiol. Infect. Dis. 30:579-586.
14. Joly-Guillou, M.L., M. Kempf, J.D. Cavallo, M. Chomarat, L. Dubreuil, J. Maugein, C. Muller-Serieys, and M. Roussel-Delvallez. 2010. Comparative in vitro activity of meropenem, imipenem and piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: A French multicentre study. BMC Infect. Dis. 10:72.
15. Lee, H., K.S. Ko, J.H. Song, and K.R. Peck. 2011. Antimicrobial activity of doripenem and other carbapenems against gram-negative pathogens from Korea. Microb. Drug Resist. 17:37-45.
16. Li, J., Nation R.L., J.D. Turnidge, R.W. Milne, K. Coulthard, C.R. Rayner, and D.L. Paterson. 2006. Colistin: The reemerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect. Dis. 6:589-601.
17. Mendes, R.E., D.J. Farrell, H.S. Sader, and R.N. Jones. 2010. Comprehensive assessment of tigecycline activity tested against a worldwide collection of Acinetobacter spp. (2005-2009). Diagn. Microbiol. Infect. Dis. 68:307-311.
18. Milatovic, D., F.J. Schmitz, J. Verhoef, and A.C. Fluit. 2003. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob. Agents Chemother. 47:400-404.
19. Nicodemo, A.C., M.R. Araujo, A.S. Ruiz, and A.C. Gales. 2004. In vitro susceptibility of Stenotrophomonas maltophilia isolates: Comparison of disc diffusion, Etest and agar dilution methods. J. Antimicrob. Chemother. 53:604-608.
20. Rubinstein, E., and D. Vaughan. 2005. Tigecycline: A novel glycylcycline. Drugs 65:1317-1336.
21. Sader, H.S., and R.N. Jones. 2005. Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. Int. J. Antimicrob. Agents 25:95-109.
22. Scheetz, M.H., J.S. Esterly, M. Malczynski, M. Postelnick, and C. Qi. 2009. Impact of dissimilar susceptibility breakpoints for doripenem on susceptibility and carbapenem discordance for Pseudomonas aeruginosa. Diagn. Microbiol. Infect. Dis. 64:465-467.
23. Tan, T.Y., L.S. Ng, and D.M. Chen. 2010. Influence of different Mueller-Hinton agars and media age on Etest susceptibility testing of tigecycline. Diagn. Microbiol. Infect. Dis. 68:93-95.
24. Turner, P.J. 2009. MYSTIC Europe 2007: Activity of meropenem and other broad-spectrum agents against nosocomial isolates. Diagn. Microbiol. Infect. Dis. 63:217-222.
25. Wang, H., M. Chen, Y. Ni, Y. Liu, H. Sun, Y. Yu, X. Yu, Y. Mei, M. Liu, Z. Sun, et al. 2010. Antimicrobial resistance among clinical isolates from the Chinese Meropenem Surveillance Study (CMSS), 2003-2008. Int. J. Antimicrob. Agents 35:227-234.
26. Wang, Y.F., and M.J. Dowzicky. 2010. In vitro activity of tigecycline and comparators on Acinetobacter spp. isolates collected from patients with bacteremia and MIC change during the Tigecycline Evaluation and Surveillance Trial, 2004 to 2008. Diagn. Microbiol. Infect. Dis. 68:73-79.
27. Yahav, D., A. Lador, M. Paul, and L. Leibovici. 2011. Efficacy and safety of tigecycline: A systematic review and metaanalysis. J. Antimicrob. Chemother. 66:1963-1971.
28. Zhanel, G.G., H.J. Adam, D.E. Low, J. Blondeau, M. Decorby, J.A. Karlowsky, B. Weshnoweski, R. Vashisht, A. Wierzbowski, and D.J. Hoban. 2011. Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: Results of the CANWARD 2007-2009 study. Diagn. Microbiol. Infect. Dis. 69:291-306.
29. Zhanel, G.G., M. DeCorby, K.A. Nichol, A. Wierzbowski, P.J. Baudry, J.A. Karlowsky, P. Lagace-Wiens, A. Walkty, M.R. Mulvey, and D.J. Hoban. 2008. Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006. Diagn. Microbiol. Infect. Dis. 62:67-80.
30. Zhanel, G.G., R. Wiebe, L. Dilay, K. Thomson, E. Rubinstein, D.J. Hoban, A.M. Noreddin, and J.A. Karlowsky. 2007. Comparative review of the carbapenems. Drugs 67:1027-1052.